Abstract：
Pancreatic cancer is still a difficult disease to treat, despite recent advances in surgical techniques and chemotherapeutic drugs. Its incidence continues to rise, as does the number of older patients. Sarcopenia is defined as a progressive and generalized loss of skeletal muscle mass and strength. Sarcopenia is present in approximately 40% in patients with pancreatic cancer. Sarcopenia is primarily diagnosed through imaging, and progress is being made in the development of automated methods and artificial intelligence, as well as biomarker research. Sarcopenia has been linked to a poor prognosis in pancreatic cancer patients. However, some studies suggest that sarcopenia is not always associated with a poor prognosis, depending on the resectability of pancreatic cancer and the nature of treatment, such as surgery or chemotherapy. Recent meta-analyses have found that sarcopenia is not linked to postoperative complications. It is still debated whether there is a link between sarcopenia and drug toxicity during chemotherapy. The relationship between sarcopenia and immunity has been investigated, but the mechanism is still unknown.
摘要：
胰腺癌仍然是一种难以治疗的疾病，尽管最近在外科技术和化疗药物方面取得了进展。发病率持续上升,老年患者的数量也是如此。肌肉减少症定义为骨骼肌质量和力量的进行性和广泛性丧失。在患有胰腺癌的患者中存在大约40%的肌肉减少症。肌肉减少症主要通过影像学诊断,自动化方法和人工智能的发展正在取得进展，以及生物标志物研究。肌肉减少症与胰腺癌患者的不良预后有关。然而,一些研究表明，肌肉减少症并不总是与不良预后相关，取决于胰腺癌的可切除性和治疗的性质，如手术或化疗。最近的荟萃分析发现，肌肉减少症与术后并发症无关。化疗期间肌肉减少症与药物毒性之间是否存在联系仍存在争议。已经研究了肌肉减少症与免疫之间的关系，但机制仍然未知。
